Targeting unmet medical needs

XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers in order to produce innovative diagnostic kits for the early detection, monitoring, and screening of cancerous cells. By exploiting the natural immune response to early stage cancer and the proprietary platform technology Combinatorial Proteomic®, XEPTAGEN has discovered specific tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. Our mission includes creating innovative tools that improve the diagnostic accuracy for cancer and the clinical management of cancer patients.

Press Releases

    •  CEA-IgM in colon cancer early stage detection assessed by AIGO in a multicenter ...  
    •  Monitoring antiviral therapy response in HCV positive cirrhotic patients by ...  
    •  Xeptagen SpA and ZBx Corporation (Toronto, Canada) agree to develop a ...  
    •  AIGO starts a multicenter prospective study to assess the diagnostic value of ...  
    •  University of Brescia validates PSA-IgM 3-fold improvement for prostate cancer ...